nalbuphine + parecoxib

Nalbuphine + parecoxib is a combination analgesic regimen primarily investigated for its synergistic effects in managing acute postoperative pain and preventing opioid-induced hyperalgesia, particularly that induced by remifentanil. Nalbuphine is a mixed opioid agonist-antagonist that acts as a potent agonist at kappa-opioid receptors and an antagonist at mu-opioid receptors, providing analgesia while potentially reducing mu-opioid-mediated side effects like pruritus and respiratory depression. Parecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor and a prodrug of valdecoxib, which reduces the synthesis of inflammatory prostaglandins. The combination is frequently studied by researchers at Zhujiang Hospital of Southern Medical University to optimize multimodal analgesia protocols and mitigate the paradoxical increase in pain sensitivity associated with high-dose intraoperative opioid use.

Other names

nalbuphine hydrochloride + parecoxib sodium